BioLineRx Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx or view top-rated stocks.

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioLineRx saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 444,600 shares, a decrease of 34.2% from the February 28th total of 675,400 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is currently 0.2 days.
View BioLineRx's Short Interest.

BioLineRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for BioLineRx.

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings data on Tuesday, February, 23rd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.36.
View BioLineRx's earnings history.

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLRX shares have increased by 79.4% and is now trading at $2.87.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued 1 year target prices for BioLineRx's shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate BioLineRx's stock price to reach $19.00 in the next year. This suggests a possible upside of 562.0% from the stock's current price.
View analysts' price targets for BioLineRx or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioLineRx include Altimmune (ALT), Akouos (AKUS), Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Geron (GERN), Selecta Biosciences (SELB), Akebia Therapeutics (AKBA), Summit Therapeutics (SMMT), Kala Pharmaceuticals (KALA), Molecular Templates (MTEM), Atreca (BCEL), Foghorn Therapeutics (FHTX), Catalyst Pharmaceuticals (CPRX), Inozyme Pharma (INZY) and Applied Therapeutics (APLT).
View all of BLRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLRX stock can currently be purchased for approximately $2.87.

BioLineRx has a market capitalization of $122.29 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

BioLineRx employs 38 workers across the globe.

The official website for BioLineRx is www.biolinerx.com.

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]